Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.57 |
| ▸ | CES1 | P23141 | 1/20 | 0.57 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.55 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.51 |
| ▸ | WNT3A | P56704 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29601697 | 1.00 | CES2 (0.57) | CES2CES1GRM4L3MBTL1LMNA | |
| SCHEMBL29601127 | 0.98 | CES2 (0.59) | CES2CES1GRM4L3MBTL1LMNA | |
| SCHEMBL504833 | 0.98 | CES2 (0.59) | CES2CES1GRM4L3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL6833226 | 0.96 | CES2 (0.57) | CES2CES1GRM4L3MBTL1LMNA | |
| Bromide SCHEMBL5121089 | 0.94 | CES2 (0.55) | CES2CES1GRM4L3MBTL1LMNA | |
| Pyridine SCHEMBL8599632 | 0.91 | L3MBTL1 (0.55) | CES2CES1GRM4L3MBTL1LMNA | |
| SCHEMBL12777709 | 0.82 | CES2 (0.59) | CES2CES1GRM4L3MBTL1LMNA | |
| SCHEMBL2470002 | 0.81 | CTNNB1 (0.71) | CES2CES1GRM4L3MBTL1LMNA | |
| SCHEMBL253276 | 0.81 | CES2 (0.64) | CES2CES1GRM4L3MBTL1LMNA | |
| SCHEMBL29355245 | 0.81 | CES2 (0.64) | CES2CES1GRM4L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219976-A1 | AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR | INCYTE CORPORATION | 2023-07-13 | — | — | US | claimed |
| US-10858372-B2 | Amorphous solid form of a BET protein inhibitor | INCYTE CORPORATION (US) | 2020-12-08 | — | — | US | claimed |
| US-20190300545-A1 | AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR | INCYTE CORPORATION | 2019-10-03 | — | — | US | claimed |
| US-10329305-B2 | Amorphous solid form of a BET protein inhibitor | INCYTE CORPORATION (US) | 2019-06-25 | — | — | US | claimed |
| US-20180273546-A1 | AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR | INCYTE CORPORATION | 2018-09-27 | — | — | US | claimed |
| US-20170121347-A1 | AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR | INCYTE CORPORATION | 2017-05-04 | — | — | US | claimed |
| WO-2017075377-A1 | AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR | INCYTE CORPORATION (US) | 2017-05-04 | — | — | WO | claimed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| EP-4626896-A1 | POLYELECTROPHILIC METALATED HETEROCYCLES DERIVED FROM 2-(PYRIDIN-2-YL)IMIDAZO[1,2-A]PYRIDINE AND USE THEREOF AS CHEMOTHERAPEUTIC AGENTS | Universidad del País Vasco/Euskal Herriko Unibertsitatea (ES) | 2025-10-08 | — | — | EP | disclosed |
| US-20250229198-A1 | COMPOUNDS FOR SEPARATION OF RARE EARTH ELEMENTS AND S-, P-, D- METALS, METHOD OF SEPARATION, AND USE THEREOF | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I (CZ) | 2025-07-17 | — | — | US | disclosed |
| EP-4585599-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd. (CN) | 2025-07-16 | — | — | EP | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| US-12268977-B2 | Compounds for separation of rare earth elements and s-, p-, d-metals, method of separation, and use thereof | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR. V.V.I. (CZ) | 2025-04-08 | — | — | US | disclosed |
| EP-0555480-A1 | NOVEL THIAZOLE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-08-18 | — | — | EP | disclosed |
| US-5026702-A | Enhances physical performance in animals, effective in lowering blood sugar, reducing body fat and lowering atherogenic lipoproteins | DR. KARL THOMAE, GMBH (DE) | 1991-06-25 | — | — | US | disclosed |
| EP-0372125-A1 | Oxazole and thiazole derivatives | AKZO N.V. (NL) | 1990-06-13 | — | — | EP | disclosed |
| EP-0368384-A1 | Thiazole derivatives | AKZO N.V. (NL) | 1990-05-16 | — | — | EP | disclosed |
| EP-0334146-A1 | Morpholines and morpholine-N-oxides, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1989-09-27 | — | — | EP | disclosed |
| US-4492695-A | ANTICONVULSANTS, SEDATIVES, TRANQUILIZERS | SYNTHELABO (FR) | 1985-01-08 | — | — | US | disclosed |
| US-4005212-A | ANTIDEPRESSANT, ANOREXIGENIC, PSYCHOENERGIZING, 2-PHENYL-2,3,5,6-TETRAHYDROIMIDAZO(2,1-B)THIAZOLE | RHONE-POULENC S.A. (FR) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121347-A1 | AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR | BRD1, BRD3, BRD2 | CES2 4856/4885CES1 4060/4885GRM4 3852/4885 |
| US-10329305-B2 | Amorphous solid form of a BET protein inhibitor | BRD1, BRD3, BRD2 | CES2 4856/4885CES1 4060/4885GRM4 3852/4885 |
| US-20230219976-A1 | AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR | BRD1, BRD3, BRD2 | CES2 4856/4885CES1 4060/4885GRM4 3852/4885 |
| US-20180273546-A1 | AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR | BRD1, BRD3, BRD2 | CES2 4854/4885CES1 4068/4885GRM4 3507/4885 |
| US-20190300545-A1 | AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR | BRD1, BRD3, BRD2 | CES2 4856/4885CES1 4060/4885GRM4 3852/4885 |
| US-20250229198-A1 | COMPOUNDS FOR SEPARATION OF RARE EARTH ELEMENTS AND S-, P-, D- METALS, METHOD OF SEPARATION, AND USE THEREOF | SCO2, SOD3, SLC39A3 | CES2 2023/4885CES1 3686/4885GRM4 3674/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | CES2 1314/4885CES1 108/4885GRM4 4718/4885 |
| US-10858372-B2 | Amorphous solid form of a BET protein inhibitor | BRD1, BRD3, BRD2 | CES2 4856/4885CES1 4060/4885GRM4 3852/4885 |
| US-12268977-B2 | Compounds for separation of rare earth elements and s-, p-, d-metals, method of separation, and use thereof | SCLY, SFXN1, PTCD3 | CES2 4075/4885CES1 3584/4885GRM4 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.